Please login to the form below

Not currently logged in
Email:
Password:

dapagliflozin

This page shows the latest dapagliflozin news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitors – such as Farxiga (dapagliflozin) – can be used to provide organ protection for patients with chronic conditions, such as heart failure and diabetes.

Latest news

More from news
Approximately 8 fully matching, plus 97 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 is the world’s largest network of verified doctors with over 6 million members across key markets; our closed and...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...